20002024

Research activity per year

Personal profile

Biography

Dr. H.M. van Santen is clinical researcher, pediatric endocrinologist, and committed to improve the endocrine outcome of children with (oncologic) disease.

"I have the vision that all children should have an optimal hormonal state enabling them to have an optimal daily quality of life and to develop and grow (comparable to their peers) into adulthood. For children with underlying disease, this requires cross-field thinking and collaboration with partners outside of one’s own domain. My mission is to improve outcome of children with any kind of disease by preventing or restoring their endocrine dysfunction. Within this mission, I focus on the key-player of the endocrine system; “the hypothalamus".


Dr. Van Santen moved her career in 2013 to Utrecht to coordinate the endocrine care for children with cancer in the Princess Máxima Center. She has co-authored > 150 papers on the endocrine effects of childhood cancer treatment, pediatric thyroid cancer , craniopharyngioma and hypothalamic dysfunction.

She is an active associate professor in the research program of Child Health, WKZ, UMCU and associate-PI in the Princess Máxima Centre for Pediatric Oncology. In the UMCU Utrecht, she is coordinator of the European Reference Centers for "Rare Hypothalamic Disease", "Pituitary tumors" and "Thyroid Tumors" and , within the Maxima, chair of the M4C Craniopharyngioma. Her research program focusses on hypothalamic dysfunction and hypothalamic obesity, craniopharyngioma, pediatric thyroid cancer and the endocrine effects of childhood cancer treatment. She is an internationally acknowledged expert on hypothalamic dysfunction and pediatric thyroid cancer with regular invited lectures both national and international.

She is the chair of the Dutch Pediatric Endocrinologists (NvK, sectie kinderendocrinologie), of the SIOPe craniopharyngioma working group, and of the European Guideline for Thyroid cancer in children. Together with the Late Effects of Childhood Cancer International Guideline Harmonization Groups (IGHG) she co-chairs the recommendations for thyroid and hypothalamic-pituitary disorders, and is member of the working groups for gonadal toxicity and preservation of fertility and metabolic syndrome.

Fellowship & awards

2020                ZonMW Stimuleringssubsidie "Implementatie van nieuw behandelalgoritme voor hypothalame obesitas bij kinderen met een supra-sellaire tumor"

2019                KIKA project: THYRO-Dynamics Study (Prospective study on thyroid function during treatment with chemotherapy in 600 children)

2019                Princess Maxima Grant; research grant for 4-year PhD student: “Building an organoid model for craniopharyngioma”

2009-2011      Fellowship kinderendocrinologie in het Emma Kinderziekenhuis AMC

Side activities

2020 - now   member of the WKZ Onderzoeksfonds Scientific Committee

2020             member of the Internal Grant committee Princess Maxima Center

2020             Chair SIOPe craniopharyngioma board

2020             Member of the Advisory board of the Academic Japanese Consortium for Juvenile Thyroid Cancer (JCJTC, president Dr Ohtsuru)  

2020             co-PI Prinses Maxima Center for Pediatric Oncology Utrecht

2019             BKO qualification UMCU

2019             Chair of the European Task Force for Recommendations of Treatment of Thyroid nodules and Carcinoma in Childhood

2016 – now  Deputy educator ( plaatsvervangend opleider) of the clinical fellow pediatric endocrinology in the Wilhelmina Children’s Hospital, UMCU

2018 - now   member of working group supportive care Princess Maxima Center

2017 - now   member of fertility working group Princess Maxima Center

2016 - now   Co-chair of the IGHG for surveillance of hypothalamic-pituitary disorders in Childhood Cancer Survivors

2016 - now   Participant/ member of the working group of the IGHG working group for  preservation of fertility in male childhood cancer survivors (in progress)

2016 – now  Participant / working group lead of the IGHG working group for preservation of fertility in female childhood cancer survivors (in progress)

2016 - now   Participant/ member of the working group of the IGHG recommendation for surveillance of the metabolic syndrome in childhood cancer survivors (in progress)

2016 - now   Co-chair of the Dutch Guideline for Treatment of Thyroid nodules and cancer in children (in progress)

2016 - now   Participant of  the SIOP supportive care group

2016 - now   Participant of the SIOP low grade glioma working group

2016 - now   Participant of the national consortium for Late effects of treatment for childhood thyroid carcinoma ( PI T Links, UMCG)

2016 - now   Participant of the consortium of the Dexadagen-2 study

2015 - now   Participant of the Dutch Growth Hormone Advisory board (SEK)

2015 - now   Consultative function for the “Cyberpoli” for thyroid diseases and craniopharyngioma(www.cyberpoli.nl)

 2015 – now    Participant of the SKION LATER Recommendations for screening Childhood Cancer Survivors https://www.skion.nl/workspace/uploads/vertaling-richtlijn-LATER-versie-final-okt-2014_2.pdf

 

External positions

Associate Group Leader - Research - Prinses Maxima Centrum

1 Jan 202331 Dec 3999

Participant of the SIOP low grade glioma working group - adviserend - SIOP

1 Jan 202231 Dec 3999

Member of the Advisory board - adviserend - Academic Japanese Consortium for Juvenile Thyroid

1 Jan 202231 Dec 3999

Chair SIOPe craniopharyngioma board - voorzitter - SIOP

1 Sept 202031 Dec 3999

"Consultative function for the “Cyberpoli” for thyroid diseases and craniopharyngioma - adviserend - Cyberpoli

1 Jan 201531 Dec 3999

Participant of the Dutch Growth Hormone Advisory board (SEK) - adviserend - SEK

1 Jan 201331 Dec 3999

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or